Genomic Testing for Improved Treatments in Breast Cancer - Episode 5

FLEX Trial: Genomic Testing of HER2 Status in ER+/HER2-Breast Cancer

,

Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.

EP. 1: Evolving Treatment Paradigms for Early-Stage Breast Cancers
EP. 2: Overview of Genomic Assays for Early-Stage Breast Cancer
EP. 3: MammaPrint: A 70-Gene Signature Test for Patient with Breast Cancer
EP. 4: Clinical Considerations of Genomic Testing in Early-Stage Breast Cancer
Now Viewing
EP. 5: FLEX Trial: Genomic Testing of HER2 Status in ER+/HER2-Breast Cancer
EP. 6: Exploring Multigene Genomic Assays in High-Risk BC Patients
EP. 7: Real-World Evidence in Genomic Testing from SABCS 2023
EP. 8: Racial Disparities and Genomic Testing for Breast Cancer Patients
EP. 9: Reflecting on Genomic Testing in Practice for Breast Cancer
EP. 10: Ongoing Studies in Genomic Testing for Breast Cancer

Related Content:

Genomic Testing for Improved Treatments in Breast CancerInsightsBreast CancerInsights Video Series
Implications of Real-World Data in the 1L Treatment of High-Risk CLL
Navigating Continuous BTKi Therapy for CLL in the 1L Setting
Clinical Decision Making to Overcome Treatment Resistance in 2L HR+ HER2- mBC